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Repeat endomyocardial biopsy was performed in 28 pa-
tients with dilated cardiomyopathy of ::;12 months' dura-
tion and either symptomatic heart failure or life-threatening
ventricular arrhythmias. Myocarditis was strongly sus-
pected clinically in all cases, yet was unconfirmed on initial
right ventricular biopsy. Seventeen patients underwent both
right and left ventricular biopsy, seven patients had a repeat
right ventricular biopsy and four patients underwent repeat
left ventricular biopsy alone. The interval between initial and
repeat biopsy averaged 31 ± 6 days.
Myocarditis was confirmed on repeat biopsy in 4 of 6
patients whose initial biopsy revealed "borderline" myo-
carditis (that is, interstitial inflammation but absence of
Endomyocardial biopsy is currently the procedure of choice
for diagnosing myocarditis because histologic confirmation
is generally considered necessary for unequivocally estab-
lishing the correct diagnosis. Although myocarditis may
occasionally demonstrate diffuse myocardial involvement, it
most frequently presents as a focal or multifocal process
0,2). Because sampling error must certainly occur as a
result of the small amount of myocardium that undergoes
biopsy in an individual patient, the true frequency with
which myocarditis exists but is not detected on right ven-
tricular biopsy is unknown.
This study reports our experience employing repeat right
and left ventricular endomyocardial biopsy in patients with
heart failure of recent onset in whom myocarditis continued
to be strongly suspected despite an initial right endomyocar-
dial biopsy that failed to provide histologic confirmation.
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myocyte necrosis) compared with none of the 22 patients
whose initial biopsy showed either myocyte hypertrophy or
interstitial fibrosis, or both (p = O'()OO7). "Borderline"
myocarditis on initial biopsy was the only clinical or
histologic finding predictive of myocarditis on subsequent
biopsy.
Repeat endomyocardial biopsy can identify and poten-
tially modify the treatment of an additional group of
patients with dilated cardiomyopathy and nondiagnostic
initial endomyocardial histologic features. Right ventricu-
lar sampling should be repeated in patients whose initial
biopsy demonstrates "borderline" myocarditis.
(J Am Coll CardioI1990;15:283-9)
Methods
Study patients. We retrospectively reviewed the medical
and pathologic records of all 384 patients who underwent at
least one right ventricular endomyocardial biopsy between
January 1, 1982 and September 1, 1988 to exclude the
diagnosis of myocarditis. From this large group, we identi-
fied a total of 28 patients who had undergone repeat endo-
myocardial biopsy of either the right or the left ventricle or
both ventricles concurrently. All 28 patients had dilated
cardiomyopathy and a left ventricular ejection fraction
::;0.45 by the radionuclide technique (3). Coronary angiog-
raphy was normal in all patients. Symptomatic heart failure
of ::;12 months' duration was present in 26 patients, and 2
patients presented with recurrent symptomatic ventricular
tachycardia.
Transvenous endomyocardial biopsy and pathologic exam-
ination. Right heart catheterization was performed in all
patients using a triple lumen thermodilution catheter. At the
conclusion of the procedure, right ventricular endomyocar-
dial biopsy was performed as previously described (4,5).
Four to seven biopsy samples (each measuring 2 to 3 mm in
diameter) were taken from the right ventricular septum and
were immediately fixed by immersion in buffered 10% for-
malin for histologic studies (5). Paraffin sections were
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'These specimens demonstrated a variety of diagnoses including normal
myocardium, myocyte hypertrophy, interstitial or replacement fibrosis, adria·
mycin cardiotoxicity, amyloidosis, sarcoidosis, hemochromatosis and Whip·
pie's disease.
Table 1. Histologic Findings on Initial and Repeat
Endomyocardial Biopsy in Patients Undergoing Biopsy
for Possible Myocarditis Between January 1, 1982 and
September 1, 1988
No. % No. %
Patients (no.) 384 100 28 7.3
Myocarditis 46 12 4 14
"Borderline" myocarditis 12 3 0 0
No myocarditis' 326 85 24 86
relation to right-sided clinical findings and ejection fraction.
No complications were encountered with any right or left
ventricular biopsy.
Statistical analysis. All group data are expressed as the
mean values ± SEM. Group comparisons were performed
using RS/I (Bolt Beranek and Newman) COMPARE soft-
ware.
Repeat BiopsyInitial Biopsy
Results
The histologic findings on initial and repeat endomyocar-
dial biopsy for all 28 patients who underwent this procedure
to exclude myocarditis as the cause for symptomatic left
ventricular dysfunction are shown in Table I. During the 6.5
years of this study, 50 cases (13%) of histologically verified
myocarditis were detected among 384 patients undergoing
biopsy. Repeat endomyocardial biopsy was performed in 7%
of the total number of patients with dilated cardiomyopathy
and was responsible for diagnosing 4 (8%) of the 50 cases of
myocarditis.
Indications for repeat biopsy. Alimited number of clinical
indications prompted clinicians to proceed with a second
endomyocardial biopsy. These included unexplained heart
failure and an initial biopsy result showing "borderline"
myocarditis (6 patients), a high clinical symptom score (7
patients), recent onset of symptomatic ventricular tachycar-
dia (2 patients) and heart failure ofabrupt onset (13 patients).
The mean duration of symptoms before medical care was
sought averaged only 1.7 ± 0.5 months in the group with
heart failure of abrupt onset compared with >6 months for
the larger group with dilated cardiomyopathy (n = 371) who
underwent initial endomyocardial biopsy to exclude myo-
carditis.
Patient characteristics and histologic findings. The clini-
cal, histologic and ventriculographic findings for the 28
patients who underwent repeat biopsy are shown in Table 2.
Patients were grouped by the presence (Group 1) or absence
(Group II) of myocarditis on repeat biopsy. The mean age for
stained with hematoxylin eosin, Masson trichrome and
Congo red. Left ventricular biopsy was performed percuta-
neOlisly through the femoral artery using a 7F long sheath
and a 7F 104 cm long bioptome (Cordis 502-300c). Multiple
biopsy specimens (generally six to seven) were taken near
the left ventncular apex and processed as described for right
ventricular biopsies.
We classified all biopsy specimens in accordance with the
Dallas criteria (6) into three major histologic groups on the
basis of an initial review of all light microscopic slides:
myocarditis, "borderline" myocarditis and no myocarditis.
Myocarditis specimens revealed an interstitial infiltrate and
associated necrosis or degeneration of adjacent myocytes.
"Borderline" myocarditis specimens contained an increase
in interstitial inflammatory cells but lacked myocyte necrosis
and, therefore, an unequivocal diagnosis could not be estab-
lished. If a scant interstitial infiltrate was seen, multiple
deeper cuts of the paraffin block were performed and addi-
tional sections reviewed. Specimens classified as showing no
myocarditis contained either normal myocardium, myocyte
hypertrophy, interstitial fibrosis or replacement fibrosis with
a few scattered inflammatory cells.
Clinical indications for repeat biopsy. The decision to
proceed with a repeat endomyocardial biopsy was made in
each case by the referring physician, and the factors that
prompted this decision were sought through an extensive
review of each patient's medical record. Indications for
repeat biopsy fell into four categories: recent onset of
unexplained heart failure, ventricular tachycardia in the
absence of valvular or coronary artery disease, "borderline"
myocarditis on initial biopsy and a high clinical suspicion of
myocarditis. We also scored the number (0 to 3) of clinical
features per patient at the onset of illness that suggested a
clinical diagnosis of myocarditis (7). These included a fe-
brile, viral illness just before the development of cardiac
symptoms (l point); pericarditis as judged by a pericardial
friction rub or pleuritic substernal chest pain (1 point); or
supportive laboratory abnormalities, including elevation of
serum creatine kinase, erythrocyte sedimentation rate or
white blood cell count (1 point). A high clinical score based
on this point system was defined as ~2. Each patient's
clinical score was subsequently correlated with biopsy find-
ings.
Right versus left ventricular biopsy. Right and left ven-
tricular endomyocardial biopsies were performed concur-
rently in 17 patients. Seven patients underwent right ventric-
ular biopsy alone (one patient had a documented left
ventricular thrombus by echocardiography that precluded
left ventricular sampling; three patients declined a left ven-
tricular biopsy and the remaining three patients underwent
repeat biopsy before the introduction of left ventricular
biopsy at our institution). The remaining four patients un-
derwent left ventricular biopsy alone, primarily to determine
the cause of disproportionate left ventricular dysfunction in
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Table 2. Clinical, Ventriculographic and Histologic Data for 28 Patients With Clinically Suspected Myocarditis Who Underwent Repeat
Endomyocardial Biopsy
Duration Biopsy Findings
of Initial Repeat Biopsy
Case Age (yr)1 Initial Clinical Illness Indication for Interval
No. Gender LVEF Score (weeks) Repeat Biopsy RV RV LV (days) Outcome*
Group I: Myocarditis on Repeat Biopsy
I 45IM 0.22 0 6 Equivocal biopsy C/W + ND 10 Improved (NYHA II)
2 70/M 0,35 0 2 Equivocal biopsy C/W + 110 Died (CHF)
3 45IM 0.13 I (P) 10 Equivocal biopsy C/W + ND 25 Improved (NYHA II)
4 58IM 0,33 3 I Equivocal biopsy C/W + ND 41 Improved (NYHA I)
Group II: No Myocarditis Detected
5 371M 0.10 3 16 Clinical score 7 Died (CHF)
6 61IM 0.12 I (V) 4 Acute CHF 7 Improved (NYHA II)
7 221M 0.12 3 3 Clinical score 42 Died (sudden)
8 51IM 0.22 2 (V, L) 3 Clinical score 24 Improved (NYHA I)
9 251M 0.45 3 I Clinical score 43 Improved (NYHA I)
10 53/F 0.18 0 16 Acute CHF 7 Died (CHF)
11 46/F 0.23 2(V, P) 16 Clinical score 35 Improved (NYHA I)
12 201M 0.08 I (V) 4 Acute CHF 4 Cardiac transplant
13 50IM 0.35 0 34 VT 61 Unimproved (NYHA II)
14 251M 0.29 0 52 Refractory VT ND 12 Unimproved (NYHA II)
15 351M 0.13 2 (V, P) 26 Equivocal biopsy C/W ND 82 Died (CHF)
16 301M 0.18 2(V, P) I Clinical score ND 42 Died (sudden)
17 311M 0.28 I (V) 6 Acute CHF ND 3 Unimproved (NYHA III)
18 251M 0.17 I (V) 2 Acute CHF 142 Cardiac transplant
19 411M 0,34 0 3 Acute CHF 44 Unimproved (NYHA II)
20 65IM 0.19 I (V) 12 Acute CHF 6 Unimproved (NYHA III)
21 191M 0.09 0 3 Acute CHF ND 9 Cardiac transplant
22 58IM 0.15 I (V) 2 Acute CHF 6 Unimproved (NYHA III)
23 79IM 0.28 2 26 Clinical score ND 6 Died (CHF)
24 371M 0.44 0 8 Acute CHF ND 20 Improved (NYHA I)
25 54IM 0.21 0 11 Acute CHF 31 Unimproved (NYHA III)
26 53/F 0.24 I 7 Acute CHF 13 Improved (NYHA II)
27 451M 0.43 I 12 Acute CHF 35 Unimproved (NYHA III)
28 331M 0.11 I 4 Equivocal biopsy C/W ND 2 Improved (NYHA I)
*New York Heart Association (NYHA) functional classification or cause of death; CHF = congestive heart failure; C/W = consistent with "borderline"
myocarditis; F = female; L = laboratory abnormalities; LV = left ventricular; LVEF = left ventricular ejection fraction; M = male; ND = not done; P =
pericarditis; RV = right ventricular; V = febrile viral illness; VT = ventricular tachycardia; + = positive for myocarditis; - = negative for myocarditis.
the entire group was 43 ± 3 years, the mean initial left ular biopsy. This patient had myocarditis detected on left
ventricular ejection fraction was 0.23 ± 0.02 and the dura- ventricular biopsy alone; concurrent right ventricular biopsy
tion of symptoms before biopsy averaged 10.4 ± 2.3 weeks. showed only myocyte hypertrophy and scattered interstitial
The interval between initial and repeat endomyocardial fibrosis.
biopsy averaged 31 ± 6 days. No difference was observed The presence of clinical symptoms or signs thought to be
between patients in Group I and Group II with regard to age, diagnostic of Coxsackie-induced myocarditis, such as fever,
gender distribution, ejection fraction, clinical score, duration pericarditis or elevation in serum creatine kinase, was not
of symptoms or repeat biopsy interval (Table 2). associated with a high yield on repeat endomyocardial
Repeat biopsy histologically established the diagnosis of biopsy. Although nine patients had a clinical score of 2 or 3
myocarditis in 4 (14%) of 28 patients. Three of these four at the time of presentation, only one patient (Case 4) was
Group I patients had multifocal lymphocytic myocarditis, found to have myocarditis on repeat biopsy and he also had
and the remaining patient had diffuse granulomatous myo- "borderline" histologic features on initial biopsy. A low
carditis. Repeat right ventricular sampling was diagnostic in clinical score (1.0 ± 0.7) was present in Group I patients and
three of the four patients. Unfortunately, only one of the did not differ from that (1.0 ± 0.2) in Group II patients, who
four Group I patients underwent both right and left ventric- had negative biopsy findings. Pericarditis was documented in
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two patients in Group I and in three patients in Group II
(p = 0.14). Supportive laboratory abnormalities were de-
tected in only 1 of the 28 patients.
"Borderline" myocarditis; Unlike clinical signs or symp-
toms, histologic findings on initial biopsy were highly pre-
dictive of subsequent biopsy results. "Borderline" myo-
carditis (Fig. l) on initial right ventricular biopsy was highly
associated with a si.Jbsequent biopsy documenting unequiv-
ocal myocarditis (Fig. 2). Myocarditis was confirmed on
repeat biopsy in 4ofthe 6patients with an initial diagnosis of
"borderline" myocarditis compared with none of the 22
patients whose initial biopsy showed either myocyte hyper-
trophy or interstitial fibrosis (p = 0.0007) (Table 3). These
four patients did not differ clinically or histologically from
the two patients with "borderline" myocarditis whose re-
peat biopsy failed to reveal myocarditis. In each case, a
thorough examination of all initial biopsy materials had
failed to confirm myocarditis.
Treatment and outcome. Immunosuppression was initi-
ated with prednisone and azathioprine after histologic con-
firmation of myocarditis in all four patients in Group I; each
of the three patients with lymphocytic myocarditis demon-
strated a substantial increase (>0.10) in left ventricular
ejection fraction and a decrease in symptomatic heart failure
(~1 New York Heart Association functional class) within 6
months of treatment. The fourth patient (Case 2) had gran-
ulomatous myocarditis and failed,to respond to treatment.
He died 5 months later of intractable heart failure.
No patient in Group II (biopsy negative) received immu-
nosuppressive therapy. Spontaneous improvement was ob-
served within 6 months in seven Group II patients who
demonstrated a decline in functional class and an increase in
left ventricular ejection fraction from 0.24 ± 0.05 to 0.49 ±
0.08 (p < 0.05). Progressive heart failure resulted in four
deaths in Group II; two patients died suddenly and three
underwent successful cardiac transplantation. The small
number of patients with myocarditis precluded any evalua-
tion of the relation between histologic features, type of
treatment and clinical outcome.
Discussion
Avariety of studies (l,7,8) have documented the difficulty
of diagnosing myocarditis with certainty on the basis of
clinical signs and symptoms, ECG findings or serologic
results. Despite recent criticisms raised by some patholo-
gists (9) concerning the sensitivity and accuracy ofendomyo-
cardial biopsy in the diagnosis of myocarditis in patients with
dilated cardiomyopathy, clinicians continue to rely on the
biopsy for pathologic confirmation of the disease. Although
the true incidence of myocarditis in this group of patients
remains uncertain, previous series (5,7,10-13) that em-
ployed endomyocardial biopsy have claimed to detect myo-
carditis in 2% to 67% of cases.
Figure 1. Photomicrographs of the initial biopsy samples from
Patients I (A), 2 (B) and 4 (C). Each specimen shows "borderline"
myocarditis with a variable number of scattered interstitial mono-
nuclear inflammatory cells but no evidence of myocyte necrosis
(Congo red; original magnification x313, reduced by 18%).
Indications for repeat biopsy in patients with "borderline"
myocarditis. The extent to which additional invasive or
noninvasive studies should be pursued in patients with
lACC Vol. 15, No.2
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Figure 2. Photomicrographs of repeat biopsy samples from Patients
1 (A) and 2 (B). There is now evidence for a prominent interstitial
mononuclear infiltrate in association with necrotic myocytes in both
specimens (Congo red; original magnification x313, reduced by
18%).
suspected myocarditis despite negative biopsy results has
never been systematically evaluated. For the first time, this
study provides data to support the recommendations of
Aretz et al. (6) that patients with "borderline" myocarditis
should undergo repeat endomyocardial biopsy. Our data
suggest that the decision to proceed with repeat biopsy
shOuld be based principally on the initial biopsy findings
rather than clinical impressions. Repeat biopsy of either the
right or the left ventricle in the absence of suggestive initial
hi~tologic features was not helpful in identifying additional
patients with focal myocarditis, even if they had heart failure
of abrupt onset «3 months) or a combination of signs or
symptoms thought to be highly suggestive of a clinical
diagnosis of myocarditis. Unexplained heart failure and
cardiomegaly of short duration, which averaged only 10.6
weeks, prompted clinicians to undertake almost 50% of the
repeat biopsies, yet none of these patients were found to
Table 3. Group Comparisons Among Patients With Myocarditis
on Repeat Biopsy (Group I), Without Myocarditis (Group II) and
the Entire Group
Entire
Group Group I Group II p Value"
No. of patients 28 4 (14%) 24 (86%)
Age (yr) 43 ± 3 55 ± 6 42 ± 3 0.06
Left ventricular 0.23 ± 0.02 0.26 ± 0.05 0.22 ± 0.02 NS
ejection fraction
Clinical score 1.1 ± 0.2 1.0 ± 0.7 1.1 ± 0.2 NS
Duration of 10.4 ± 2.3 4.8 ± 2 11.3 ± 2.5 NS
symptoms
before biopsy
(weeks)
Repeat biopsy 31 ± 6 47 ± 22 28 ± 6 NS
interval (days)
"Borderline" 6(21%) 4 (100%) 2 (8%) 0.0007
myocarditis (on
initial biopsy)
"Group I versus Group II.
have myocarditis when their initial biopsies demonstrated
only interstitial fibrosis or myocyte hypertrophy. Despite the
small amount of myocardium sampled during each biopsy
and the often focal nature of myocarditis, our findings
support those of Weiland et al. (14) that right ventricular
biopsy generally does provide representative information
about the presence or absence of myocardial inflammation.
Implications for therapy. Although the effects of immu-
nosuppressive therapy on the clinical outcome of myocardi-
tis remain controversial, this form of therapy had been
contemplated in all 28 patients in this study who underwent
repeat biopsy. In view of the many known side effects and
risks of this form of treatment and the cUlTent lack of
controlled studies demonstrating the efficacy of immunosup-
pressive agents in patients with "borderline" histologic
findings, it has been our policy to administer such agents
only to patients with biopsy-verified myocarditis. Repeat
biopsy significantly altered clinical management in 14% of
these patients by providing the necessary histologic confir-
mation to initiate immunosuppressive therapy. Although
three of four treated patients with myocarditis demonstrated
improvement in ventricular function, no conclusion should
be drawn regarding the relation between treatment and
outcome because therapy was not assigned in a prospective,
randomized or controlled manner and because spontaneous
improvement in left ventricular function was observed in
seven of the Group II patients with negative biopsy findings.
Right versus left ventricular biopsy. The exact incidence
with which right ventricular biopsy fails to detect myocardial
inflammation remains uncertain and is certainly dependent
on the type of patient undergoing biopsy as well as the
number and location of samples obtained. The optimal
number of samples remains to be defined in a systematic
manner, but most centers obtain at least five samples per
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patient. Furthermore, because most patients undergo this
procedure as part of the evaluation of signs and symptoms
related to left ventricular dysfunction, sampling error related
to right ventricular sampling alone may occur. Richardson et
al. (15) compared right and biventricular biopsy in 15 pa-
tients with chronic dilated cardiomyopathy and demon-
strated no major histologic differences. However, they did
not detect a single case of myocarditis in their study. More
recently, Weiland et at. (14) found that right ventricular
biopsy generally provided representative information about
diseases that affect the left ventricular myocardium, but their
autopsy series as well as more recent data from Unverferth
et at. (16) have shown that left ventricular biopsy can
provide additional morphometric information. Unfortu-
nately, left ventricular biopsy was performed in only one of
the six patients with "borderline" myocarditis so its true
utility in this group of patients remains uncertain.
It is not hard to imagine that certain cases of myocarditis
can affect the left ventricle to a substantially greater degree
than the right ventricle. In this regard, the findings of
concurrent right and left ventricular biopsy were of special
interest. Results of repeat biventricular biopsy were discor-
dant in only 1of 17 patients. Myocarditis was detected only
on left ventricular biopsy in a 70 year old man who had
left-sided heart failure and minimal right-sided findings. It is
uncertain whether this patient had myocarditis confined
primarily to the left ventricle or whether failure to detect
myocardial inflammation on right ventricular biopsy was due
to the focal nature of the disease itself. An autopsy per-
formed after 5 months of immunosuppressive therapy dis-
closed evidence for healed myocarditis in the left ventricle
and minimal right ventricular involvement. Although we did
not encounter any complications, the reported potentially
higher morbidity of left ventricular biopsy in early studies
(17) argues against its routine use in this group of patients.
Limitations of the study. This study evaluated the role of
repeat biopsy in a limited number of patients with symptom-
atic dilated cardiomyopathy. Because no attempt was made
to perform repeat biopsy in all patients with dilated cardio-
myopathy or those with more long-standing symptoms, the
yield of repeat sampling in this much larger group of patients
remains undefined. Furthermore, the role of noninvasive
screening techniques before repeat biopsy was not consid-
ered. It is possible that noninvasive radionuclide cardiac
imaging employing 'an inflammation-avid radioisotope such
as gallium-67 (18,19), myocardial necrosis-avid indium-Ill
antimyosin monoclonal antibodies (20) or nuclear magnetic
resonance imaging (21) may have been able to identify a
subgroup of patients with a high yield on repeat biopsy. The
recent availability of reliable immunohistologic techniques
for identifying leukocytes and T lymphocytes in paraffin
sections may also prove useful for the pathologic diagnosis
of myocarditis. However, the sensitivity and specificity of
each of these techniques in the initial diagnosis of myocardi-
tis continue to be debated and none has yet been employed
to guide further management of patients with negative bi-
opsy findings. Because not all patients underwent biventric-
ular biopsy, the true discordance rate between right and left
ventricular sampling in the detection of myocarditis remains
uncertain. Finally, selection bias may have occurred as a
result of the nonprospective selection of patients for repeat
biopsy and resulted in an abnormally high rate of detection
of myocarditis on repeat biopsy.
Conclusions. Myocarditis remains difficult to diagnose
clinically and often histologically because of the extreme
lack of specificity of associated clinical signs and symptoms
and its focal or multifocal myocardial involvement, respec-
tively. The diagnosis should continue to be suspected in
individuals with unexplained heart failure of short duration
whose initial biopsy findings are suggestive but not diagnos-
tic of myocarditis. Repeat right ventricular biopsy should be
undertaken in such patients because it can be expected to
correctly identify additional patients with previously uncon-
firmed myocarditis. Until such time as either sensitive and
specific noninvasive methods have been developed and
validated for the detection of myocarditis or the optimal
management of "borderline" myocarditis has been defined,
repeat endomyocardial biopsy should be considered in all
patients in whom immunosuppressive therapy is being con-
templated, but whose initial biopsy reveals "borderline"
myocarditis.
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